If you have been reading about lipogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
== Precision fermentation == Precision fermentation is an approach to manufacturing specific functional products which intends to minimise the production of unwanted by-products through the application of synthetic biology, particularly by generating synthetic "cell factories" with engineered genomes and metabolic pathways optimised to produce the desired compounds as efficiently as possible with the available resources. Precision fermentation of genetically modified microorganisms may be used to manufacture proteins needed for cell culture media, providing for serum-free cell culture media in the manufacturing process of cultured meat. A 2021 publication showed that photovoltaic-driven microbial protein production could use 10 times less land for an equivalent amount of protein compared to soybean cultivation. Some Food Regulatory Agencies such as the FDA do not require the labeling of precision fermented foods as GMO since they are produced by, but do not contain the genetically engineered organisms. It is unclear how regulation will be handled in EU markets, with some startups such as Formo and Those Vegan Cowboys forming the Food Fermentation Europe (FFE) alliance together with other alt-protein startups to seek regulatory approval.
== Military == The Armed Forces of Serbia and Montenegro (Serbian: Војска Србије и Црне Горе/Vojska Srbije i Crne Gore, ВСЦГ/VSCG), previously known as Army of Yugoslavia (Serbian: Војска Југославије/Vojska Jugoslavije, ВЈ/VJ) included ground forces with internal and border troops, naval forces, air and air defense forces, and civil defense. It was established from the remnants of the Yugoslav People's Army (JNA), the military of the SFR Yugoslavia. Several Bosnian Serb units of the VJ were transferred over to the Republika Srpska, during the course of the Bosnian War, leaving only units directly from Serbia and Montenegro in the armed forces. The VJ saw military action during the Yugoslav Wars, including the Siege of Dubrovnik, as well as the Kosovo War, and played combat roles during ethnic insurgencies. Following the Kosovo War, the VJ was forced to evacuate Kosovo, and in 2003 it was renamed the ''Armed Forces of Serbia and Montenegro.'' Following the dissolution of the Union between Serbia and Montenegro, units from each army were assigned to the independent republics of Serbia and Montenegro, as recruitment in the army was on a local, rather than Federal, level. Montenegro inherited the small navy of the FR Yugoslavia, due to Serbia being landlocked.
Psychiatric care may be required following recovery. A liver transplant may be required if damage to the liver becomes severe. The need for transplant is often based on low blood pH, high blood lactate, poor blood clotting, or significant hepatic encephalopathy. With early treatment, liver failure is rare. Death occurs in about 0.1% of cases. Paracetamol poisoning was first described in the 1960s. Rates of poisoning vary significantly between regions of the world. In the United States more than 100,000 cases occur a year. In the United Kingdom it is the medication responsible for the greatest number of overdoses. Young children are most commonly affected. In the United States and the United Kingdom, paracetamol is the most common cause of acute liver failure.
Sources: en.wikipedia.org
the Bundesanstalt für vereinigungsbedingte Sonderaufgaben, BvS (Federal Agency for Unification-related Special Tasks), which managed remaining state-owned enterprises: the Treuhandliegenschaftsgesellschaft (now TLG Immobilien GmbH), which manages the remaining state-owned urban and industrial real estate. the Bodenverwertungs- und -verwaltungs GmbH (BVVG), a subsidiary of the Treuhand created in 1992, which manages the state-owned agricultural land, forest lands, and related real estate. The BvS ceased operations at the end of 2000, but it remains legally in existence; its remaining tasks are all delegated to other bodies. TLG and BVVG remain the largest real estate owners in the new federal states. In 2000, TLG was reoriented from focussing on privatisation of its assets to "active portfolio management" with a view to making profits for the German federal government. By 2007, having sold 45,000 properties in six years and reinvested 1.5 billion euros, it was still managing 1500 properties worth 1.4 billion euros. The planned privatisation of TLG itself was put on hold in July 2008 because of adverse economic conditions. In January 2020, TLG Immobilien was acquired by the Luxembourg-domiciled property company Aroundtown. In July 2008, the BVVG announced total privatization receipts of 3.5 billion euros since its establishment in 1992, which it had gained through the sale of around 525,000 hectares (1,300,000 acres) of agricultural land, with a similar amount of forest land and a small amount of other land.
In Japan, indigo became especially important during the Edo period. This was due to a growing textiles industry, and because commoners had been banned from wearing silk, leading to the increasing cultivation of cotton, and consequently indigo – one of the few substances that could dye it. In North America, indigo was introduced into colonial South Carolina by Eliza Lucas, where it became the colony's second-most important cash crop (after rice). As a major export crop, indigo supported plantation slavery there. In the May and June 1755 issues of The Gentleman's Magazine, there appeared a detailed account of the cultivation of indigo, accompanied by drawings of necessary equipment and a prospective budget for starting such an operation, authored by South Carolina planter Charles Woodmason. It later appeared as a book. By 1775, indigo production in South Carolina exceeded 1,222,000 pounds. When Benjamin Franklin sailed to France in November 1776 to enlist France's support for the American Revolutionary War, 35 barrels of indigo were on board the Reprisal, the sale of which would help fund the war effort. In colonial North America, three commercially important species are found: the native I. caroliniana, and the introduced I. tinctoria and I. suffruticosa. In the UK the structure of Natural Indigo was still being sought in 1878 when Edward Schunck published on Indigo e.g. Blue from Polygonum tinctorium and By other Plants (16 April 1878) to the Manchester Literary and Philosophical Society
The caffeine content of most Monster Energy drinks is approximately 10 mg/oz (33.81 mg / 100 mL), or 160 mg for a 16oz (473 mL) can. The packaging usually contains a warning label advising consumers against drinking more than 48oz per day (500 mL per day in Australia). The drinks are not recommended for children, pregnant or nursing women, or people sensitive to caffeine. The ingredients include carbonated water, sucrose, glucose, citric acid, natural flavors, taurine, sodium citrate, color added, panax ginseng root extract, L-carnitine L-tartrate, caffeine, sorbic acid, benzoic acid, niacinamide, sodium chloride, Glycine max glucuronolactone, inositol, guarana seed extract, pyridoxine hydrochloride, sucralose, riboflavin, maltodextrin, and cyanocobalamin.
=== Music === Doillon's love for music was enkindled by her father: "When my parents split, I discovered with Jacques, his taste for eclectic and a strange form of radicalness in music. He would say: 'sit down, shut up and listen to the music' while playing records from Chet Baker, Billie Holiday, Siouxsie and the Banshees, Patti Smith and Nick Drake." She often quotes Bob Dylan and Leonard Cohen, and mentions Lhasa, Lead Belly, Fiona Apple, Cat Power, Nina Simone, Tim Buckley and Bobbie Gentry as her influences. Doillon recorded with many musicians in New York and Paris during the 2000s before starting a solo career in 2010. Her genre has been described as haunted folk, and her voice has been described as "equal parts Marianne Faithfull, Nina Simone, Anohni and Joanna Newsom." She writes her songs on Canadian Guild guitars (D55) or the piano and performs on an Eko electric guitar.
Sources: en.wikipedia.org
It has been shown that injection of peptide amphiphile solutions in vivo leads to in situ gel formation due to the presence of counterions in physiological solutions. This, along with the complete biodegradability of the materials, suggests numerous applications in in vitro and in vivo therapies.
Acrokeratoelastoidosis of Costa (keratoelastoidosis marginalis) Aquagenic keratoderma (acquired aquagenic palmoplantar keratoderma, aquagenic syringeal acrokeratoderma, aquagenic wrinkling of the palms, transient reactive papulotranslucent acrokeratoderma) Bart–Pumphrey syndrome (palmoplantar keratoderma with knuckle pads and leukonychia and deafness) Camisa disease Carvajal syndrome (striate palmoplantar keratoderma with woolly hair and cardiomyopathy, striate palmoplantar keratoderma with woolly hair and left ventricular dilated cardiomyopathy) Corneodermatoosseous syndrome (CDO syndrome) Diffuse epidermolytic palmoplantar keratoderma (palmoplantar keratoderma cum degeneratione granulosa Vörner, Vörner's epidermolytic palmoplantar keratoderma, Vörner keratoderma) Diffuse nonepidermolytic palmoplantar keratoderma (diffuse orthohyperkeratotic keratoderma, hereditary palmoplantar keratoderma, keratosis extremitatum progrediens, keratosis palmoplantaris diffusa circumscripta, tylosis, Unna–Thost disease, Unna–Thost keratoderma) Erythrokeratodermia variabilis (erythrokeratodermia figurata variabilis, keratosis extremitatum progrediens, keratosis palmoplantaris transgrediens et progrediens, Mendes da Costa syndrome, Mendes da Costa type erythrokeratodermia, progressive symmetric erythrokeratoderma) Focal acral hyperkeratosis (acrokeratoelastoidosis lichenoides, degenerative collagenous plaques of the hand) Focal palmoplantar and gingival keratosis Focal palmoplantar keratoderma with oral mucosal hyperkeratosis (focal epidermolytic palmoplantar keratoderma, hereditary painful callosities, hereditary painful callosity syndrome, keratosis follicularis, keratosis palmoplantaris nummularis, nummular epidermolytic palmoplantar keratoderma) Haim–Munk syndrome (palmoplantar keratoderma with periodontitis and arachnodactyly and acro-osteolysis) Hidrotic ectodermal dysplasia (alopecia congenita with keratosis palmoplantaris, Clouston syndrome, Clouston's hidrotic ectodermal dysplasia, Fischer–Jacobsen–Clouston syndrome, keratosis palmaris with drumstick fingers, palmoplantar keratoderma and clubbing) Howel–Evans syndrome (familial keratoderma with carcinoma of the esophagus, focal non-epidermolytic palmoplantar keratoderma with carcinoma of the esophagus, palmoplantar ectodermal dysplasia type III, palmoplantar keratoderma associated with esophageal cancer, tylosis, tylosis–esophageal carcinoma) Hystrix-like ichthyosis–deafness syndrome (HID syndrome) Keratoderma climactericum (acquired plantar keratoderma, climacteric keratoderma, Haxthausen's disease) Keratosis punctata palmaris et plantaris (Buschke–Fischer–Brauer disease, Davis Colley disease, keratoderma disseminatum palmaris et plantaris, keratosis papulosa, keratoderma punctatum, keratodermia punctata, keratoma hereditarium dissipatum palmare et plantare, palmar and plantar seed dermatoses, palmar keratoses, papulotranslucent acrokeratoderma, punctate keratoderma, punctate keratoses of the palms and soles, maculosa disseminata) Keratitis–ichthyosis–deafness syndrome (erythrokeratodermia progressiva Burns, ichthyosiform erythroderma with corneal involvement and deafness, KID syndrome) Mal de Meleda (acral keratoderma, Gamborg–Nielsen keratoderma, mutilating palmoplantar keratoderma of the Gamborg–Nielsen type, palmoplantar ectodermal dysplasia type VIII, palmoplantar keratoderma of the Norrbotten type) Naxos syndrome (diffuse non-epidermolytic palmoplantar keratoderma with woolly hair and cardiomyopathy, diffuse palmoplantar keratoderma with woolly hair and arrythmogenic right ventricular cardiomyopathy of Naxos, Naxos disease) Olmsted syndrome (mutilating palmoplantar keratoderma with periorificial keratotic plaques, mutilating palmoplantar keratoderma with periorificial plaques, polykeratosis of Touraine) Pachyonychia congenita type I (Jadassohn–Lewandowsky syndrome) Pachyonychia congenita type II (Jackson–Lawler pachyonychia congenita, Jackson–Sertoli syndrome) Palmoplantar keratoderma and spastic paraplegia (Charcot–Marie–Tooth disease with palmoplantar keratoderma and nail dystrophy) Palmoplantar keratoderma of Sybert (Greither palmoplantar keratoderma, Greither syndrome, keratosis extremitatum hereditaria progrediens, keratosis palmoplantaris transgrediens et progrediens, Sybert keratoderma, transgrediens and progrediens palmoplantar keratoderma) Papillon–Lefèvre syndrome (palmoplantar keratoderma with periodontitis) Porokeratosis plantaris discreta Punctate palmoplantar keratoderma Schöpf–Schulz–Passarge syndrome (eyelid cysts with palmoplantar keratoderma and hypodontia and hypotrichosis) Scleroatrophic syndrome of Huriez (Huriez syndrome, palmoplantar keratoderma with scleroatrophy, palmoplantar keratoderma with sclerodactyly, scleroatrophic and keratotic dermatosis of the limbs, sclerotylosis) Striate palmoplantar keratoderma (acral keratoderma, Brünauer–Fuhs–Siemens type of palmoplantar keratoderma, focal non-epidermolytic palmoplantar keratoderma, keratosis palmoplantaris varians, palmoplantar keratoderma areata, palmoplantar keratoderma striata, Wachter keratoderma, Wachters palmoplantar keratoderma) Spiny keratoderma (porokeratosis punctata palmaris et plantaris, punctate keratoderma, punctate porokeratosis of the palms and soles) Tyrosinemia type II (oculocutaneous tyrosinemia, Richner–Hanhart syndrome) Vohwinkel syndrome (keratoderma hereditaria mutilans, keratoma hereditaria mutilans, mutilating keratoderma of Vohwinkel, mutilating palmoplantar keratoderma)
The penultimate process is called conching. A conche is a container filled with metal beads, which act as grinders. The refined and blended chocolate mass is kept in a liquid state by frictional heat. Before conching, chocolate has an uneven and gritty texture. The conching process produces cocoa and sugar particles smaller than the tongue can detect (typically around 20 μm) and reduces rough edges, hence the smooth feel in the mouth. The length of the conching process determines the final smoothness and quality of the chocolate. After the process is complete, the chocolate mass is stored in tanks heated to about 45–50 °C (113–122 °F) until final processing. After conching, chocolate is tempered to crystallize a small amount of cocoa butter. Cocoa butter is a polymorphic fat with six different crystal forms, but only one of them—Form V—gives chocolate its characteristic snap, gloss, and stable texture. Tempering eliminates the undesirable crystal forms and promotes the formation of Form V. After chocolate has been tempered, it is molded into different shapes, including chocolate bars and chocolate chips.
The so-called Stele of the Vultures, now in the Louvre, is a fragmented limestone stele found in Telloh, (ancient Girsu) Iraq, in 1881. The stele is reconstructed as having been 1.8 metres (5 ft 11 in) high and 1.3 metres (4 ft 3 in) wide and was set up c. 2450 BCE. It was erected as a monument of the victory of Eannatum of Lagash over Ush, king of Umma, leading to a boundary treaty with his successor Enakalle of Umma. On it, various incidents in the war are represented. In one register, the king (his name appears inscribed around his head) stands in front of his phalanx of heavily armoured soldiers, with a curved weapon in his right hand, formed of three bars of metal bound together by rings. In another register a figure, the king, his name again inscribed around his head, rides on his chariot in the thick of the battle, while his kilted followers, with helmets on their heads and lances in their hands, march behind him. On the other side of the stele is an image of Ninurta, a god of war, holding the captive Ummaites in a large net. This implies that Eannatum attributed his victory to Ninurta, and thus that he was in the god's protection (though some accounts say that he attributed his victory to Enlil, the patron deity of Lagash). The victory of Eannatum is mentioned in a fragmentary inscription on the stele, suggesting that after the loss of 3,600 soldiers on the field, Ush, king of Umma, was killed in a rebellion in his capital city of Umma: “[…] (Eannatum) defeated him.
Amino acids (two proteinogenic: cysteine and methionine, and many other non-coded: cystine, taurine, etc.) and two vitamins (biotin and thiamine) are organosulfur compounds crucial for life. Many cofactors also contain sulfur, including glutathione, and iron–sulfur proteins. Disulfides, S–S bonds, confer mechanical strength and insolubility of the (among others) protein keratin, found in outer skin, hair, and feathers. Sulfur is one of the core chemical elements needed for biochemical functioning and is an elemental macronutrient for all living organisms.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.